Literature DB >> 30210700

Survival associated alternative splicing events in diffuse large B-cell lymphoma.

Rui Zhang1, Peng Lin2, Xia Yang1, Rong-Quan He3, Hua-Yu Wu4, Yi-Wu Dang1, Yong-Yao Gu1, Zhi-Gang Peng3, Zhen-Bo Feng1, Gang Chen1.   

Abstract

Growing evidence has revealed that the initiation of various malignancies is closely associated with alternative splicing (AS) events in certain key oncogenes. However, in diffuse large B-cell lymphoma (DLBCL), there is still a great deal to learn about AS variants. In this study, 33,724 AS variant profiles were obtained from 16,278 genes in 48 DLBCL cases. A total of 10 AS variants were identified as overall survival (OS)- related events via multivariate Cox regression analysis. Notably, alternative donor (AD) sites in AS events in the low-risk group showed a significantly better outcome in DLBCL patients than in the high-risk group (P=0.0002). The area under the curve (AUC) of the receiver-operator characteristic curve (ROC) for ADs in DLBCL was 0.746. Furthermore, 66 related splicing factors were obtained to investigate their potential correlations with AS events. Factors SF1, HNRNPC, HNRNPD, and HNRNPH3 were significantly involved in different OS-related AS variants. Collectively, we constructed valuable prognostic predictors for DLBCL patients and mapped novel splicing networks for further investigation of the underlying mechanisms related to AS variants in DLBCLs.

Entities:  

Keywords:  Alternative splicing; correlation network; diffuse large B-cell lymphoma; prognosis

Year:  2018        PMID: 30210700      PMCID: PMC6129525     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  46 in total

1.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.

Authors:  Margaret A Shipp; Ken N Ross; Pablo Tamayo; Andrew P Weng; Jeffery L Kutok; Ricardo C T Aguiar; Michelle Gaasenbeek; Michael Angelo; Michael Reich; Geraldine S Pinkus; Tane S Ray; Margaret A Koval; Kim W Last; Andrew Norton; T Andrew Lister; Jill Mesirov; Donna S Neuberg; Eric S Lander; Jon C Aster; Todd R Golub
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

3.  A "liaison dangereuse" between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK.

Authors:  Mohamad Fawal; Florence Armstrong; Severine Ollier; Henri Dupont; Christian Touriol; Bernard Monsarrat; Georges Delsol; Bernard Payrastre; Dominique Morello
Journal:  Blood       Date:  2006-07-11       Impact factor: 22.113

4.  PTPROt: an alternatively spliced and developmentally regulated B-lymphoid phosphatase that promotes G0/G1 arrest.

Authors:  R C Aguiar; Y Yakushijin; S Kharbanda; S Tiwari; G J Freeman; M A Shipp
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

5.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene.

Authors:  Rotem Karni; Elisa de Stanchina; Scott W Lowe; Rahul Sinha; David Mu; Adrian R Krainer
Journal:  Nat Struct Mol Biol       Date:  2007-02-18       Impact factor: 15.369

6.  Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors.

Authors:  J F Cáceres; S Stamm; D M Helfman; A R Krainer
Journal:  Science       Date:  1994-09-16       Impact factor: 47.728

7.  Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies.

Authors:  G Salles; M Zain; W M Jiang; V A Boussiotis; M A Shipp
Journal:  Blood       Date:  1993-12-15       Impact factor: 22.113

8.  A mix of S and ΔS variants of STAT3 enable survival of activated B-cell-like diffuse large B-cell lymphoma cells in culture.

Authors:  M Zheng; K B Turton; F Zhu; Y Li; K M Grindle; D S Annis; L Lu; A C Drennan; D J Tweardy; U Bharadwaj; D F Mosher; L Rui
Journal:  Oncogenesis       Date:  2016-01-04       Impact factor: 7.485

9.  Human omental adipose-derived mesenchymal stem cell-conditioned medium alters the proteomic profile of epithelial ovarian cancer cell lines in vitro.

Authors:  Yanling Zhang; Weihong Dong; Junjie Wang; Jing Cai; Zehua Wang
Journal:  Onco Targets Ther       Date:  2017-03-17       Impact factor: 4.147

10.  Systematic analysis of mutation distribution in three dimensional protein structures identifies cancer driver genes.

Authors:  Akihiro Fujimoto; Yukinori Okada; Keith A Boroevich; Tatsuhiko Tsunoda; Hiroaki Taniguchi; Hidewaki Nakagawa
Journal:  Sci Rep       Date:  2016-05-26       Impact factor: 4.379

View more
  9 in total

1.  Experimental factors are associated with fetal fraction in size selection noninvasive prenatal testing.

Authors:  Longwei Qiao; Jun Mao; Minjuan Liu; Yinghua Liu; Xiaoyan Song; Hui Tang; Qing Zhang; Hong Li; Yaojuan Lu; Yuting Liang; Ting Wang
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

2.  Wide-ranging analysis of survival-related alternative splicing events in invasive breast carcinoma.

Authors:  Keren Jia; Yingcheng Wu; Jing Huang; Jianing Chen; Huagen Wei; Huiqun Wu
Journal:  Oncol Lett       Date:  2020-06-05       Impact factor: 2.967

3.  A predicted risk score based on the expression of 16 autophagy-related genes for multiple myeloma survival.

Authors:  Fang-Xiao Zhu; Xiao-Tao Wang; Hui-Qiong Zeng; Zhi-Hua Yin; Zhi-Zhong Ye
Journal:  Oncol Lett       Date:  2019-09-19       Impact factor: 2.967

4.  Expression of N6-methyladenosine (m6A) regulators correlates with immune microenvironment characteristics and predicts prognosis in diffuse large cell lymphoma (DLBCL).

Authors:  Zucheng Xie; Meiwei Li; Haoyuan Hong; Qingyuan Xu; Zhendong He; Zhigang Peng
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Landscape of Alternative Splicing Events Related to Prognosis and Immune Infiltration in Glioma: A Data Analysis and Basic Verification.

Authors:  Hong-Xin Su; Gang Yang; Fei Su; Chen-Xiao Hu; Tao Zhang; Jun-Tao Ran; Quan-Lin Guan
Journal:  J Immunol Res       Date:  2022-07-04       Impact factor: 4.493

6.  Prognostic value and prospective molecular mechanism of miR-100-5p in hepatocellular carcinoma: A comprehensive study based on 1,258 samples.

Authors:  Qing-Lin He; Shan-Yu Qin; Lin Tao; Hong-Jian Ning; Hai-Xing Jiang
Journal:  Oncol Lett       Date:  2019-10-04       Impact factor: 2.967

7.  Identification of prognostic splicing factors and exploration of their potential regulatory mechanisms in pancreatic adenocarcinoma.

Authors:  Min-Hua Rong; Zhan-Hui Zhu; Ying Guan; Mei-Wei Li; Jia-Shuo Zheng; Yue-Qi Huang; Dan-Ming Wei; Ying-Mei Li; Xiao-Ju Wu; Hui-Ping Bu; Hui-Liu Peng; Xiao-Lin Wei; Guo-Sheng Li; Ming-Xuan Li; Ming-Hui Chen; Su-Ning Huang
Journal:  PeerJ       Date:  2020-02-11       Impact factor: 2.984

8.  Role of alternative splicing signatures in the prognosis of glioblastoma.

Authors:  Zu-Cheng Xie; Hua-Yu Wu; Yi-Wu Dang; Gang Chen
Journal:  Cancer Med       Date:  2019-11-01       Impact factor: 4.452

9.  Weighted gene co expression network analysis (WGCNA) with key pathways and hub-genes related to micro RNAs in ischemic stroke.

Authors:  Xiang Qu; Shuang Wu; Jinggui Gao; Zhenxiu Qin; Zhenhua Zhou; Jingli Liu
Journal:  IET Syst Biol       Date:  2021-05       Impact factor: 1.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.